Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $15 price tar...
This allows for the treatment of patients with major depressive disorder (MDD) ages 22 to 86, changing the previous upper age l...
Oppenheimer analyst Steven Lichtman maintains BrainsWay (NASDAQ:BWAY) with a Outperform and raises the price target from $10...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target ...
This would represent growth of 16% to 26% over full-year 2023 revenue. In addition, it continues to anticipate that profitabili...
BrainsWay (NASDAQ:BWAY) reported quarterly sales of $9.095 million which beat the analyst consensus estimate of $8.720 million ...
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasi...
